Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Iressa To The Rescue: Oncology Stocks Stand Out On Wall Street

Executive Summary

Millennium's multiple myeloma agent Velcade is leading the parade of oncologic therapies attracting renewed enthusiasms from investors

You may also be interested in...



Ranexa Run-Up Shows Breadth Of Biotech Rally On Wall Street

CV Therapeutics is a quiet beneficiary of the FDA advisory committee decision regarding the risk of QT prolongation with GSK/Bayer's erectile dysfunction agent Levitra and Sanofi's benign prostatic hyperplasia treatment UroXatral

Ranexa Run-Up Shows Breadth Of Biotech Rally On Wall Street

CV Therapeutics is a quiet beneficiary of the FDA advisory committee decision regarding the risk of QT prolongation with GSK/Bayer's erectile dysfunction agent Levitra and Sanofi's benign prostatic hyperplasia treatment UroXatral

Iressa Approval Upholds Standard For Oncology Subpart H Approvals – FDA

The Iressa approval upholds the current standard of approval for oncology drugs under the Subpart H accelerated approval regulations, FDA maintains

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS041783

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel